MetaCap

Bioventus Inc. Class A (BVS)

NASDAQ: BVSHealth CareMedical/Dental InstrumentsUSD

9.88-0.07 (-0.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BVS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$676.53M
52-week range
7.02 – 15.89
Day range
9.81 – 10.17
Volume / Avg
612.43K / 536.81K
Beta
—

52-week range

$7.02$15.89

BVS stock today

Shares of Bioventus (BVS) finished lower on Nov 20 at $9.88, a drop of 0.70% or $0.07 per share, versus the S&P 500's 3.70% decline. Shares are 37.8% below their 52-week high of $15.89, set on Aug 5, 2026 and 40.8% above the 52-week low of $7.02, in the middle of the past year's range. BVS is up 32.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 36.5%.

Bioventus trades at 12.2x its trailing twelve-month earnings per share of $0.81. Its forward P/E of 11.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Bioventus

Company profile

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.

Industry
Medical/Dental Instruments
CEO
Mr. Robert E. Claypoole
Headquarters
Durham, NC
Employees
960
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Bioventus generated $568.1 million in revenue, down 0.9% from fiscal 2024, its first annual decline since 2020. Net income was $22.7 million, for a net margin of 4.0% versus a median of -6.3% in the prior 5 years. Gross margin was 68.3% (up from 67.7%) and operating margin 9.5%.

Bioventus annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$568.09M$573.28M$512.35M$512.12M$430.90M
Growth-0.91%+11.89%+0.04%+18.85%+34.17%
Net income$22.73M$-36.13M$-156.23M$-158.70M$19.38M
EPS (diluted)$0.33$-0.56$-2.49$-2.59$-0.15

Analyst forecast

Forecast

Consensus (5 analysts)

none

Avg. price target

$16.60+68.02%

  • Strong buy 2
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $15.00High $18.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$0.08 vs $0.17
Surprise
-52.94%

BVS news

All BVS news

Bioventus peers

Health Care sector
BVS peer companies
CompanyPrice% ChgMarket capCompare
DCTHDelcath Systems Inc.18.79-2.34%$653.67Mvs BVS
BBNXBeta Bionics Inc.13.36+0.30%$726.34Mvs BVS
VVVVvVARDIS Holding AG Class A14.55-3.00%$770.91Mvs BVS
TCMDTactile Systems Technology Inc.25.60-1.50%$573.48Mvs BVS
SGHTSight Sciences Inc.10.18-4.14%$565.79Mvs BVS
KIDSOrthoPediatrics Corp.31.74-2.37%$828.75Mvs BVS
RCELAvita Medical Inc.15.62-2.31%$494.96Mvs BVS
CARLCarlsmed Inc.17.42+1.16%$477.38Mvs BVS

Indexes, lists and sector

Bioventus stock FAQ

What is Bioventus's stock price today?

BVS last traded at $9.88 as of Nov 20, 4:00 PM EST, down 0.70% on the day. Prices are delayed at least 15 minutes.

What is BVS's P/E ratio?

BVS trades at a trailing P/E ratio of 12.20 and a forward P/E of 11.13.

Who is Bioventus's CEO?

Mr. Robert E. Claypoole is the chief executive officer of Bioventus Inc. Class A, which has about 960 employees.

What is the BVS 52-week high?

The 52-week high for BVS is $15.89 and the 52-week low is $7.02. The stock is currently 37.8% below its high.

Compare BVS